This study delves into the safety and effectiveness of combining hyperthermic intraoperative thoraco-abdominal chemotherapy (HITAC) with cytoreductive surgery (CRS) in patients with peritoneal carcinomatosis (PC) who need diaphragm resection. Researchers compared HITAC to traditional intraperitoneal chemotherapy (HIPEC). Results show that HITAC is a viable option with similar safety profiles, and it might offer benefits for […]
Category: Cytoreductive Surgery & Peritoneum
Mesenteric Lymph Nodes Not Linked to Ovarian Cancer Survival
Researchers examined the role of mesenteric lymph nodes (MLNs) in digestive resection for advanced ovarian cancer (OC) with peritoneal metastases. Out of 159 patients, 77 underwent digestive resection, with 61.1% having MLNs examined, and 56.8% showed involvement. Surprisingly, MLN status didn’t significantly impact overall survival or progression-free survival. This calls for further systematic and standardized […]
Repeat Cytoreduction and HIPEC Boost Survival in Recurrent Appendiceal Adenocarcinoma
When dealing with recurring mucinous appendiceal adenocarcinoma, undergoing repeat cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can be a game-changer. This study from MD Anderson Cancer Center reveals that patients who opt for repeat CRS/HIPEC enjoy similar recurrence-free survival compared to those initially treated, and even better overall survival than patients relying solely on […]
Systemic Chemotherapy’s Impact in Colorectal Peritoneal Metastases Patients Undergoing CRS-HIPEC
In patients with colorectal peritoneal metastases (CRC-PM) treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), systemic chemotherapy (SC) did not significantly enhance overall survival (OS). However, the timing of SC made a difference. Preoperative SC correlated with more major complications and shorter disease-free intervals, while postoperative SC resulted in longer disease-free intervals. The study […]